Neurodegeneration

Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort

Retrieved on: 
Wednesday, January 18, 2023
Cloud, Biomarker, NYSE, Genetics, Partnership, Cloud computing, Drug discovery, Clinical trial, Microsoft, Aircraft, Temple of Azure Clouds, MRK, Alzheimer's disease, Investment, Neurodegeneration, Pharmaceutical industry, Merck

BOSTON, Jan. 17, 2023 /PRNewswire/ - Perceiv AI announced that the company has been selected by Merck ( NYSE: MRK ) for the inaugural Merck Digital Sciences Studio (MDSS) cohort, along with eight other early-stage biomedical startups from a pool of 152 applicants.

Key Points: 
  • BOSTON, Jan. 17, 2023 /PRNewswire/ - Perceiv AI announced that the company has been selected by Merck ( NYSE: MRK ) for the inaugural Merck Digital Sciences Studio (MDSS) cohort, along with eight other early-stage biomedical startups from a pool of 152 applicants.
  • "Being selected for the Merck MDSS program is a major accomplishment for Perceiv AI and a testament to the hard work and dedication of our team.
  • Perceiv AI joins Andson Biotech , Deep Forest Sciences , Gesund.ai , Magna Labs , IndyGeneUS AI , SciMar ONE , Stem Pharm , and Pepper Bio in the 10-month accelerator program.
  • This announcement comes on the heels of Perceiv AI 's closing of its financial round at the end of last year.

Indian Researchers from ACTREC Discover Novel Therapeutic Agent for a Host of Diseases

Retrieved on: 
Tuesday, January 17, 2023
Neurodegeneration, Cell, Fatality, Atomic energy, Metastasis, DNA damage (naturally occurring), Chromosome, Chromatin, Cytokine, Acral lentiginous melanoma, DNA, Copper, Resveratrol, Surgical oncology, Diarrhea, Treatment, Copper toxicity, Genetically modified bacteria, Emeritus, DNA repair, Protein, Patient, Saliva, Sepsis, Mouse, Bone marrow, Transplant, Research, Vomiting, Serum, Tata Memorial Centre, Inflammation, Incidence, Alzheimer's disease, RESCU, Department of Atomic Energy, ACTREC, Docetaxel, Translational research, Vaccine, TMC, Cancer

MUMBAI, India, Jan. 17, 2023 /PRNewswire/ -- Chromatin comprises a complex mixture of DNA and proteins and forms the structural basis of chromosomes in the cellular nuclei. When cells die, they release cell-free chromatin particles or "cfChPs" into the circulatory system. Emerging evidence indicates that cfChPs exert toxic effects by damaging the DNA of healthy cells and activating pro-inflammatory processes. Researchers from the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), India, have recently demonstrated therapeutic benefits of a pro-oxidant mixture of resveratrol and copper, R-Cu, in patients undergoing chemotherapy for advanced gastric cancer. Combining R with Cu (R-Cu) leads to the generation of free oxygen radicals which can inactivate the offending cfChPs.

Key Points: 
  • When cells die, they release cell-free chromatin particles or "cfChPs" into the circulatory system.
  • Emerging evidence indicates that cfChPs exert toxic effects by damaging the DNA of healthy cells and activating pro-inflammatory processes.
  • Researchers from the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), India, have recently demonstrated therapeutic benefits of a pro-oxidant mixture of resveratrol and copper, R-Cu, in patients undergoing chemotherapy for advanced gastric cancer .
  • Combining R with Cu (R-Cu) leads to the generation of free oxygen radicals which can inactivate the offending cfChPs.

Metabolon Expands Inflammation Portfolio with Targeted Panels for Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation

Retrieved on: 
Tuesday, January 17, 2023
Disease, Multiple sclerosis, Neurodegeneration, Swelling, Parkinson's disease, Inflammation, Broadband, Huntington's disease, Lipid, Organic acid, Learning, Portfolio, Fertility, Chronic pain, Precision medicine, Degenerative disease, Biomarker, Pregnancy, Dermatitis, Metabolomics, Neuro, Appetite, Research, Acquisition, Alzheimer's disease, Pain, Vaccine, Pharmaceutical industry, Sphingolipid, Metabolon, Cannabinoid

MORRISVILLE, N.C., Jan. 17, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant expansion of its Inflammation Portfolio with the launch of new Targeted Panels studying Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation. The Portfolio also includes the recently launched Oxysterols Targeted Panel. Metabolon's Inflammation Portfolio detects and provides deeper insights into a wide range of known bioactive mediators of inflammation for the prediction, early detection, and monitoring of disease states, including chronic pain, neuro-inflammatory disease, neurodegeneration, and cardiovascular diseases.

Key Points: 
  • The Metabolon Sphingolipid Targeted Panel measures changes in 61 lipid species across five lipid classes with strong links to inflammation.
  • Lipid mediators of inflammation are a group of molecules involved in immune response and inflammation.
  • The balanced production and regulation of lipid mediators of inflammation are important for maintaining normal immune function and preventing chronic inflammation.
  • The Metabolon Lipid Mediators of Inflammation Targeted Panel detects 58 analytes associated with metabolic consequences of widespread inflammatory disease to identify biomarkers and their quantitative changes.

Metabolon Expands Inflammation Portfolio with Targeted Panels for Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation

Retrieved on: 
Tuesday, January 17, 2023
Disease, Multiple sclerosis, Neurodegeneration, Swelling, Parkinson's disease, Inflammation, Broadband, Huntington's disease, Lipid, Organic acid, Learning, Portfolio, Fertility, Chronic pain, Precision medicine, Degenerative disease, Biomarker, Pregnancy, Dermatitis, Metabolomics, Neuro, Appetite, Research, Acquisition, Alzheimer's disease, Pain, Vaccine, Pharmaceutical industry, Sphingolipid, Metabolon, Cannabinoid

MORRISVILLE, N.C., Jan. 17, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant expansion of its Inflammation Portfolio with the launch of new Targeted Panels studying Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation. The Portfolio also includes the recently launched Oxysterols Targeted Panel. Metabolon's Inflammation Portfolio detects and provides deeper insights into a wide range of known bioactive mediators of inflammation for the prediction, early detection, and monitoring of disease states, including chronic pain, neuro-inflammatory disease, neurodegeneration, and cardiovascular diseases.

Key Points: 
  • The Metabolon Sphingolipid Targeted Panel measures changes in 61 lipid species across five lipid classes with strong links to inflammation.
  • Lipid mediators of inflammation are a group of molecules involved in immune response and inflammation.
  • The balanced production and regulation of lipid mediators of inflammation are important for maintaining normal immune function and preventing chronic inflammation.
  • The Metabolon Lipid Mediators of Inflammation Targeted Panel detects 58 analytes associated with metabolic consequences of widespread inflammatory disease to identify biomarkers and their quantitative changes.

VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

Retrieved on: 
Thursday, January 19, 2023
Health Technology, Manufacturing, Technology, Pharmaceutical, Infectious Diseases, Genetics, Clinical Trials, Other Technology, Other Manufacturing, Science, Biotechnology, Other Science, Nursing, Health, Research, AAV, ALS, Sequence, Genome, CNS, Gene expression, DNA, Therapy, Neurodegeneration, Vectorial addition chain, Vaccine

Hundreds of millions of DNA elements are screened for their ability to serve as promoters or enhancers, driving gene expression in a cell- or disease-specific manner.

Key Points: 
  • Hundreds of millions of DNA elements are screened for their ability to serve as promoters or enhancers, driving gene expression in a cell- or disease-specific manner.
  • VectorY is a leader in the development of transformative vectorized antibody therapies for neurodegenerative diseases with high unmet medical need.
  • VectorY is advancing a pipeline of potentially disease-modifying treatments for devastating neurodegenerative diseases, including ALS, Huntington’s, and Parkinson’s disease.
  • “VectorY is a leading example of novel advanced approaches to vectorized antibody therapy development,” Joris van Arensbergen CEO of Annogen adds.

FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Disease, Caregiver, MS, CSE, Degenerative disease, Quality of life, FRA, FSD, Patient, Multiple sclerosis, CTA, Clinical trial, Sclerosis, Neurodegeneration, Pharmaceutical industry

“This is an exciting time for our company, shareholders, and most importantly for the MS community,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma.

Key Points: 
  • “This is an exciting time for our company, shareholders, and most importantly for the MS community,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma.
  • “Multiple Sclerosis is a debilitating disease without any cure, relegating patients and caregivers to significantly lower quality of life.
  • Lucid-MS is a promising first-in-class agent with a novel mechanism of action with a potential to address progressive stages of the disease.
  • We are optimistic about the potential of Lucid-MS and we are eager to initiate this clinical trial taking this one step closer to the patients.”

Global Monoclonal Antibodies Market 2023 to 2033: Players Include Merck & Co, Abbott Laboratories, Biogen and AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Health, Biotechnology, Royal commission, Mab, Knowledge, Degenerative disease, Conditional sentence, Neurodegeneration, Growth, Region, Therapy, Patient, European Commission, Workforce, Research, Cancer, NSA product types, Atlas, Bristol Myers Squibb, Incidence, USD, Mesothelioma, EC, Fine chemical, Vaccine, Pharmaceutical industry, Ipilimumab

The "Monoclonal Antibodies Market by Source Type, Production Type, Application, End Use, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoclonal Antibodies Market by Source Type, Production Type, Application, End Use, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • The monoclonal antibodies market size is estimated to be USD 189,432 million in 2022 and is expected to witness a CAGR of 11.42% during the forecast period 2023-2033.
  • Strategic initiatives performed by top companies for the development of mAb products is expected to drive the market.
  • For instance, Atlas Antibodies AB and T-Cure Bioscience, Inc. collaborated together to produce and supply CT83 mAbs in October 2021.

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

Retrieved on: 
Thursday, January 12, 2023
Health, Genetics, General Health, Research, Science, Biotechnology, Neurodegeneration, XPA, ChromaDex, SAB, University of Copenhagen Center for Planetary Research, Teaching hospital, University, Ageing, Publication, NR, Molecular biology, Xeroderma pigmentosum, DNA, University Hospital (Newark, New Jersey), Degenerative disease, City, NAD, Stanford University, National Institutes of Health, Neurology, DNA repair, Infection, Oxidative stress, Laboratory, National Institute on Aging, Research, Cockayne syndrome, NIH, Cell, United States Air Force Scientific Advisory Board, Medical device, Diabetes, Ataxia–telangiectasia, Biochemistry

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc.
  • Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative disease with over 590 journal publications.
  • His research has been conducted in models of Alzheimer’s disease, age-related hearing loss and other conditions resulting from age-related decline.
  • “Dr.

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Retrieved on: 
Wednesday, January 11, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, NPC1, Cell, Expanded access, CYTH, Brain, CSF, Therapy, Trial of the century, Society, Niemann–Pick disease, Death, MD, Lysosome, Commencement at Central Connecticut State University, AD, Cholesterol, Family, Conference, Diagnosis, Patient, Molecular genetics, 24S-Hydroxycholesterol, HIV disease progression rates, Research, Science, Serum, Organ dysfunction, Cerebrospinal fluid, Metabolism, Doctor of Philosophy, Genetic disorder, Neurodegeneration, Pharmaceutical industry, Medical device, Medical imaging, NPC

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today provided updates for the Company’s Trappsol® Cyclo™ clinical program and provided a summary of key achievements in 2022, focused on our clinical portfolio of two neurodegenerative diseases with major unmet medical needs.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today provided updates for the Company’s Trappsol® Cyclo™ clinical program and provided a summary of key achievements in 2022, focused on our clinical portfolio of two neurodegenerative diseases with major unmet medical needs.
  • We recently announced the commencement of patient enrollment and dosing in our early AD clinical study and are dedicated to building momentum for that program.
  • For more information about the Company’s Trappsol® Cyclo™ clinical program for the treatment of NPC1, visit www.ClinicalTrials.gov and reference identifiers NCT02939547 , NCT02912793 , NCT03893071 and NCT04860960 .
  • For more information about the Company’s Trappsol® Cyclo™ clinical program for the treatment of early AD and Expanded Access program, visit www.ClinicalTrials.gov and reference identifiers NCT05607615 and NCT03624842 , respectively.

Myrtelle and rAAVen Therapeutics to Develop Novel Gene Therapy Vectors

Retrieved on: 
Wednesday, January 11, 2023
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Inc., Myrtelle Canavan, Therapy, AAV, CNS, Rita Raave, Partnership, Nervous system, Central nervous system, Neuroscience, Canavan disease, Neuron, Research, Disorder, Doctor of Philosophy, Secondary research, Neurodegeneration, Vaccine, Pharmacology

Myrtelle Inc. , (“Myrtelle”) a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and rAAVen Therapeutics , (“rAAVen”) an AAV engineering company focused on generating innovative vectors for the next generation of gene therapies, today announced a partnership to develop novel recombinant adeno-associated virus (“rAAV”) vectors to advance gene therapy treatments for diseases of the central nervous system (CNS) in which myelin is affected.

Key Points: 
  • Myrtelle Inc. , (“Myrtelle”) a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and rAAVen Therapeutics , (“rAAVen”) an AAV engineering company focused on generating innovative vectors for the next generation of gene therapies, today announced a partnership to develop novel recombinant adeno-associated virus (“rAAV”) vectors to advance gene therapy treatments for diseases of the central nervous system (CNS) in which myelin is affected.
  • When myelin is damaged or does not develop normally, these impulses slow down and affect normal brain function.
  • Myrtelle will test the vectors in a range of myelin-based disorders and, if successful, pursue further development.
  • “We appreciate the opportunity to help Myrtelle achieve their goals for their novel gene therapy programs.